Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00033553 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
69
Enrollment target

NCT00033553 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 69 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00033553, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
69 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor to plan treatment may result in more effective radiation therapy. It is not yet known which chemotherapy and/or radiation therapy regimen is more effective in treating non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of different combination chemotherapy regimens and 3-dimensional radiation therapy in treating patients who have unresectable stage III non-small cell lung cancer.

Interventions

  • DRUG carboplatin
  • DRUG paclitaxel
  • RADIATION radiation therapy
  • DRUG gemcitabine hydrochloride

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2002-03
Est. Completion 2010-06
Phase Phase 2

What the Registry Record Tells You About NCT00033553

The ClinicalTrials.gov registry entry for NCT00033553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.

NCT00033553 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00033553 about?

NCT00033553 is a clinical study titled "Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor to plan treatment may result in ...

What is the current status of trial NCT00033553?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2002-03. Estimated completion is 2010-06.

What interventions are being tested in trial NCT00033553?

The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00033553?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.